Open‐label trial of a single‐day induction onto buprenorphine extended‐release injection for users of heroin and fentanyl

Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

(2019) Barbara R Haight et al.   LANCET

Fentanyl, fentanyl analogs and novel synthetic opioids: A comprehensive review

(2018) Patil Armenian et al.   NEUROPHARMACOLOGY

Weekly and Monthly Subcutaneous Buprenorphine Depot Formulations vs Daily Sublingual Buprenorphine With Naloxone for Treatment of Opioid Use Disorder

(2018) Michelle R. Lofwall et al.   JAMA Internal Medicine

Overdose Deaths Involving Opioids, Cocaine, and Psychostimulants — United States, 2015–2016

(2018) Puja Seth et al.   MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT

Fentanyl: Receptor pharmacology, abuse potential, and implications for treatment

(2018) Sandra D. Comer et al.   NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS

Population Pharmacokinetic Modeling After Repeated Administrations of RBP-6000, a New, Subcutaneously Injectable, Long-Acting, Sustained-Release Formulation of Buprenorphine, for the Treatment of Opioid Use Disorder

(2016) Celine M. Laffont et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Sustained-Release Buprenorphine (RBP-6000) Blocks the Effects of Opioid Challenge With Hydromorphone in Subjects With Opioid Use Disorder

(2016) Azmi F. Nasser et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

The Fentanyl Story

(2014) Theodore H. Stanley   JOURNAL OF PAIN

Uniform assessment and ranking of opioid Mu receptor binding constants for selected opioid drugs

(2011) Donna A. Volpe et al.   REGULATORY TOXICOLOGY AND PHARMACOLOGY